论文部分内容阅读
目的比较培美曲塞(PEM)联合顺铂(DDP)与多西他赛(DOC)联合DDP治疗晚期非小细胞肺癌的临床疗效及不良反应。方法将30例晚期非小细胞肺癌(ⅢB～Ⅳ期)患者随机分为培美曲塞加顺铂组(PC组)和多西他赛加顺铂组(DC组),每组15例。治疗2个周期后评价疗效及不良反应。结果 PC组疾病控制率为86.7%;DC组疾病控制率为80%。两组比较差异均无统计学意义(均P>0.05)。PC组Ⅲ-Ⅳ度骨髓抑制及胃肠道反应显著低于DC组(P<0.05)。结论培美曲塞联合顺铂治疗晚期非小细胞肺癌的疗效与多西他赛加顺铂的疗效相当,但不良反应发生率低,可作为晚期非小细胞肺癌患者的一线治疗。
Objective To compare the clinical efficacy and side effects of pemetrexed (PEM) plus cisplatin (DDP) and docetaxel (doc) in combination with DDP in the treatment of advanced non-small cell lung cancer. Methods Thirty patients with advanced non-small cell lung cancer (stage ⅢB-Ⅳ) were randomly divided into pemetrexed plus cisplatin group (PC group) and docetaxel plus cisplatin group (DC group), 15 cases in each group. After 2 cycles of treatment evaluation of efficacy and adverse reactions. Results The rate of disease control in PC group was 86.7%. The disease control rate in DC group was 80%. There was no significant difference between the two groups (all P> 0.05). Myelosuppression and gastrointestinal reaction were significantly lower in PC group than those in DC group (P <0.05). Conclusion Pemetrexed combined with cisplatin in the treatment of advanced non-small cell lung cancer has the same curative effect as docetaxel plus cisplatin, but the incidence of adverse reactions is low and can be used as first-line treatment for patients with advanced non-small cell lung cancer.